Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Peroxisome proliferator-activated receptor gamma (PPARgamma), the molecular target of a class of insulin sensitizers, regulates adipocyte differentiation and lipid metabolism. A dominant negative P467L mutation in the ligand-binding domain of PPARgamma in humans is associated with severe insulin resistance and hypertension. Homozygous mice with the equivalent P465L mutation die in utero. Heterozygous mice grow normally and have normal total adipose tissue weight. However, they have reduced interscapular brown adipose tissue and intra-abdominal fat mass, and increased extra-abdominal subcutaneous fat, compared with wild-type mice. They have normal plasma glucose levels and insulin sensitivity, and increased glucose tolerance. However, during high-fat feeding, their plasma insulin levels are mildly elevated in association with a significant increase in pancreatic islet mass. They are hypertensive, and expression of the angiotensinogen gene is increased in their subcutaneous adipose tissues. The effects of P465L on blood pressure, fat distribution, and insulin sensitivity are the same in both male and female mice regardless of diet and age. Thus the P465L mutation alone is sufficient to cause abnormal fat distribution and hypertension but not insulin resistance in mice. These results provide genetic evidence for a critical role for PPARgamma in blood pressure regulation that is not dependent on altered insulin sensitivity.

[1]  T. Coffman,et al.  Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. , 2000, Hypertension.

[2]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[3]  G. Williams,et al.  The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. , 1999, Diabetes.

[4]  Young-Bum Kim,et al.  Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity, β Cell Dysfunction, and Type 2 Diabetes , 2001, Cell.

[5]  S. O’Rahilly,et al.  The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.

[6]  C. Kahn,et al.  Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. , 2000, The Journal of clinical investigation.

[7]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[8]  HiroakiMatsubara Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases , 1998 .

[9]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[10]  B. Lowell,et al.  Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. , 2001, Cell.

[11]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[12]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[13]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[14]  J. Greer,et al.  Targeting genes for self-excision in the germ line. , 1999, Genes & development.

[15]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[16]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[17]  N. Maeda,et al.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Tianxin Yang,et al.  Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. , 1999, American journal of physiology. Renal physiology.

[19]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[20]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[21]  S. O’Rahilly,et al.  Digenic inheritance of severe insulin resistance in a human pedigree , 2002, Nature Genetics.

[22]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[23]  A. Garg,et al.  A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .

[24]  E. Furth,et al.  Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. , 2001, Nature medicine.

[25]  R. Burcelin,et al.  Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.

[26]  D. Scott,et al.  A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. , 2001, Biochimie.

[27]  C. Kahn,et al.  Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. , 2003, Diabetes.

[28]  A. Schäffer,et al.  Genetic modifiers of the insulin resistance phenotype in mice. , 2000, Diabetes.

[29]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[30]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[31]  S. O’Rahilly,et al.  Depot-related gene expression in human subcutaneous and omental adipocytes. , 1998, Diabetes.

[32]  Y. Deshaies,et al.  PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. , 2003, Diabetes.

[33]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[34]  P. Libby,et al.  PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. , 2000, The Journal of clinical investigation.

[36]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[37]  J. Stamler,et al.  Weight and blood pressure. Findings in hypertension screening of 1 million Americans. , 1978, JAMA.

[38]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[39]  P. Ferré,et al.  Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. , 2002, American journal of physiology. Endocrinology and metabolism.

[40]  I. Gabriely,et al.  Differential Gene Expression Between Visceral and Subcutaneous Fat Depots , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[41]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .

[42]  S. Aizawa,et al.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.

[43]  T. Ogihara,et al.  Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. , 1995, American journal of hypertension.

[44]  R. Davisson,et al.  Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. , 2001, Physiological genomics.

[45]  A. Medvedev,et al.  Transcriptional Regulation of the Mouse Uncoupling Protein-2 Gene , 2001, The Journal of Biological Chemistry.

[46]  A. Pfeiffer,et al.  Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.

[47]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[48]  H. Uozumi,et al.  Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo , 2002 .

[49]  R. Scott Weight and Blood Pressure , 1948, British medical journal.

[50]  S. Engeli,et al.  Physiology and pathophysiology of the adipose tissue renin-angiotensin system. , 2000, Hypertension.

[51]  A. Fukamizu,et al.  Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  S. Kiechl,et al.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. , 1998, Diabetes.

[53]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[54]  R. Hegele,et al.  PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. , 2002, Diabetes.

[55]  T. Kotchen,et al.  Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. , 1993, The American journal of physiology.

[56]  P. Weidmann,et al.  Insulin, insulin sensitivity and hypertension. , 1990, Journal of hypertension.

[57]  K. Takeda,et al.  Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .